Massachusetts And Paris

NATICK, Massachusetts and PARIS, May 23, 2011 - - 12-Month Clinical Data Demonstrate Low Adverse Event Rates for Boston Scientific's 2.25 mm PROMUS Element Platinum Chromium Stent Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element(TM) Everolimus-Eluting Platinum Chromium Stent System in treating small vessel coronary disease.